Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Samsung, SK Hynix to Unveil Record AI and Semiconductor Investment Plans Worth Over $646 Billion 
Italy Investigates Microsoft Over Microsoft 365 AI Subscription Price Hike 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
China Eastern Orders 25 Airbus A330neo Jets in $9.35 Billion Deal to Boost International Expansion 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Nomura Stock Upgraded to Buy by BofA as Stronger ROE and Earnings Growth Boost Outlook 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
CAMBRIDGE, Mass., Feb. 28, 2017 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will present at the Cowen and Company 37th Annual Health Care Conference. The presentation is scheduled for Tuesday, March 7th at 10:40 a.m. ET.
The webcast of the presentation will be available live on the “Investors” section of the company’s website located at www.momentapharma.com. A replay of the presentation will be posted on the Momenta website approximately one hour after the event.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 [email protected]
